Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,002
datasets available to search
ShareScore release 0.9.0
Dataset results
2,002 results for “sarcoma”
Goldengate Methylation analysis: Ewing Sarcoma
GEO Series GSE36857. Homo sapiens. 146 samples. Type: Methylation profiling by array.
Data from: Clinical factors associated with long-term complete remission versus poor response to chemotherapy in HIV-infected children and adolescents with Kaposi sarcoma receiving bleomycin and vincristine: a retrospective observational study
Kaposi sarcoma (KS) is the most common HIV-associated malignancy in children and adolescents in Africa. Pediatric KS is distinct from adult disease. We evaluated the clinical characteristics associated with long-term outcomes. We performed a retrospective observational analysis of 70 HIV-infected children and adolescents with KS less than 18 years of age diagnosed between 8/2010 and 6/2013 in Lilongwe, Malawi. Local first-line treatment included bleomycin and vincristine plus nevirapine-based highly active anti-retroviral therapy (HAART). Median age was 8.6 years (range 1.7–17.9); there were 35 females (50%). Most common sites of presentation were: lymph node (74%), skin (59%), subcutaneous nodules (33%), oral (27%), woody edema (24%), and visceral (16%). Eighteen (26%) presented with lymphadenopathy only. Severe CD4 suppression occurred in 28%. At time of KS diagnosis, 49% were already on HAART. Overall, 28% presented with a platelet count < 100 x 109/L and 37% with hemoglobin < 8 g/dL. The 2-year event-free (EFS) and overall survival (OS) were 46% and 58% respectively (median follow-up 29 months, range 15–50). Multivariable analysis of risk of death and failure to achieve EFS demonstrated that visceral disease (odds ratios [OR] 19.08 and 11.61, 95% CI 2.22–163.90 and 1.60–83.95 respectively) and presenting with more than 20 skin/oral lesions (OR 9.57 and 22.90, 95% CI 1.01–90.99 and 1.00–524.13 respectively) were independent risk factors for both. Woody edema was associated with failure to achieve EFS (OR 7.80, 95% CI 1.84–33.08) but not death. Univariable analysis revealed that lymph node involvement was favorable for EFS (OR 0.28, 95% CI 0.08–0.99), while T1 TIS staging criteria, presence of cytopenias, and severe immune suppression were not associated with increased mortality. Long-term complete remission is achievable in pediatric KS, however outcomes vary according to clinical presentation. Based on clinical heterogeneity, treatment according to risk-stratification is necessary to improve overall outcomes.
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
ClinicalTrials.gov study NCT05448820. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
ClinicalTrials.gov study NCT01438554. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
ClinicalTrials.gov study NCT00335751. IPD Sharing: NO. Countries: 1. Publications: 0.
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
ClinicalTrials.gov study NCT06050434. IPD Sharing: NO. Countries: 1. Publications: 0.
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
ClinicalTrials.gov study NCT05941325. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
ClinicalTrials.gov study NCT03450122. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Molecular Mechanism Study of Uterine Sarcoma
ClinicalTrials.gov study NCT05881967. IPD Sharing: Not stated. Countries: 1. Publications: 0.
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
ClinicalTrials.gov study NCT06298916. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma
ClinicalTrials.gov study NCT04065152. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
ClinicalTrials.gov study NCT04593758. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
ClinicalTrials.gov study NCT07066982. IPD Sharing: NO. Countries: 1. Publications: 0.
Sarcomas and DDR-Inhibition; a Combined Modality Study
ClinicalTrials.gov study NCT05116254. IPD Sharing: NO. Countries: 1. Publications: 0.
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
ClinicalTrials.gov study NCT01567046. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
ClinicalTrials.gov study NCT04551430. IPD Sharing: NO. Countries: 1. Publications: 0.
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
ClinicalTrials.gov study NCT03242382. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
ClinicalTrials.gov study NCT06699472. IPD Sharing: NO. Countries: 1. Publications: 0.
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）
ClinicalTrials.gov study NCT05167994. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
ClinicalTrials.gov study NCT00822848. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.